ALK and non-small cell lung carcinoma: In the Keynote 024 trial, in first-line treatment with pembrolizumab versus platinum doublet in advanced NSCLC, PDL1 ≥ 50%, and no sensitizing mutation of the epidermal growth factor receptor gene (EGFR) or translocation of the anaplastic lymphoma kinase gene (ALK), after overlapping curves in the first 3 months, PFS at 6 months was 62% vs. 50.3%, meaning that 38% of patients were in progression or deceased [12].